Method of producing a polypeptide or virus of interest in a continuous cell culture

US9650612B2 · US · B2

Patent metadata
FieldValue
Publication numberUS-9650612-B2
Application numberUS-201314050710-A
CountryUS
Kind codeB2
Filing dateOct 10, 2013
Priority dateJul 31, 2009
Publication dateMay 16, 2017
Grant dateMay 16, 2017

How to read this patent

A practical reading order for non-experts. Skip the full description unless you need deep technical detail.

  1. Title

    What the patent document calls the invention.

  2. Abstract

    A short plain-language summary of the technical disclosure.

  3. Assignees and inventors

    Who owns or filed the patent and who is credited as inventor.

  4. Key dates

    Filing, priority, publication, and grant dates set the timeline.

  5. First independent claim

    The legal scope of protection — read this for what is actually claimed.

  6. CPC / IPC classifications

    Technology tags used to group this patent with similar filings.

  7. Citations and related patents

    Prior art links and similar publications in this corpus.

Abstract

Official abstract text for this publication.

Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d −1 , and a cell density of less than about 2×10 7 cell/mL. Also described herein is a method for producing a polypeptide and/or virus of interest in a continuous cell culture, the method comprising culturing mammalian cells expressing the polypeptide and/or virus of interest in a continuous cell culture system, which comprises a cell retention device, wherein the cell culture system has a dilution rate (D) of less than about 2 d −1 , and a cell density of less than about 2×10 7 cell/mL; and recovering the polypeptide and/or virus of interest from medium of the cell culture system.

First claim

Opening claim text (preview).

The invention claimed is: 1. A method for producing a virus of interest in a continuous cell culture, said method comprising (a) culturing mammalian cells expressing the virus of interest in a continuous cell culture system, wherein said cell culture system comprises a cell retention device and has a dilution rate (D) of less than 0.8 d −1 and a cell density of less than 2×10 7 cell/mL, wherein the cell retention device produces a cell retention rate of less than 90%; and (b) recovering said virus of interest from medium removed from said cell culture system. 2. The method of claim 1 , wherein said dilution rate is between 0.1 and 0.8 d −1 . 3. The method of claim 1 , wherein said cell density is less than 1×10 7 cell/mL. 4. The method of claim 1 , wherein said cell culture system has a ratio of the dilution rate and a specific growth rate (D/μ) between 1.2 and 5. 5. The method of claim 1 , wherein said cell culture system has a specific growth rate of between 0.2 d −1 and 0.8 d −1 . 6. The method of claim 1 , wherein said cells are cultured in said cell culture system for more than 20 days. 7. The method of claim 1 , wherein said cells are cultured in said cell culture system for more than 40 days. 8. The method of claim 1 , wherein said cells are cultured in said cell culture system for more than 50 days. 9. The method of claim 1 , wherein said dilution rate and said cell density are maintained for at least 80% of the time the cells are cultured in said cell culture system. 10. The method of claim 1 , wherein said cell retention device comprises a macroporous microcarrier. 11. The method of claim 1 , wherein said cells are cultured in a serum-free medium. 12. The method of claim 1 , wherein said cells are cultured in at least 250 L of medium. 13. The method of claim 1 , wherein said cells are non-anchorage dependent cells. 14. The method of claim 1 , further comprising, before the culturing step, pre-culturing the cells in suspension. 15. The method of claim 1 , wherein said cells are genetically modified to express said virus of interest. 16. The method of claim 15 , wherein said cells are CHO cells.

Assignees

Inventors

Classifications

  • relating to complementing cells and packaging systems for producing virus or viral particles · CPC title

  • having a known sequence of two or more amino acids, e.g. glutathione · CPC title

  • Metalloendopeptidases (3.4.24) · CPC title

  • Xeno-free medium · CPC title

  • using catalysts, e.g. selective catalysts · CPC title

Patent family

Related publications grouped by family.

External sources

Frequently asked questions

Answers are generated from the same data shown on this page.

What does patent US9650612B2 cover?
Described herein is a chemostat-like continuous cell culture system that combines certain advantages of perfusion open systems and chemostat open systems to improve the culturing of mammalian cells, e.g., genetically modified cells, particularly in serum-free or chemically-defined media. The continuous culture system described herein involves culturing mammalian cells in a continuous cell cultu…
Who is the assignee on this patent?
Baxalta GmbH, Baxalta Inc
What technology area does this patent fall under?
Primary CPC classification C12N7/00. Mapped technology areas include Chemistry & Metallurgy.
When was this patent published?
Publication date Tue May 16 2017 00:00:00 GMT+0000 (Coordinated Universal Time) (B2). Legal status and post-grant events are not shown on this page.
What related patents are in patentsdb?
We list 8 related publications on this page (citations in our corpus or others sharing the same primary CPC).